Overview

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)

Status:
NOT_YET_RECRUITING

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

To estimate the safety and efficacy of hepatic artery infusion chemotherapy (HAIC) combine Tislelizumab and Lenvatinib (HAI-TIS-LEN) in the Treatment of hepatocellular carcinoma (HCC) with type IV(Vp4) portal vein tumor thrombus (PVTT).

Phase:

PHASE2

Details

Lead Sponsor:

Li Xiao Wei

Treatments:

lenvatinib
tislelizumab